Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 9/20 | 0.38 |
| ▸ | XIAP | P98170 | 8/20 | 0.38 |
| ▸ | BIRC3 | Q13489 | 5/20 | 0.38 |
| ▸ | CASP9 | P55211 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.38 |
| ▸ | TNF | P01375 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL819268 | 1.00 | BIRC2 (0.38) | BIRC2XIAPBIRC3CASP9CYP3A4 | |
| SCHEMBL818170 | 0.88 | XIAP (0.41) | BIRC2XIAPBIRC3CASP9CYP3A4 | |
| SCHEMBL823086 | 0.88 | XIAP (0.41) | BIRC2XIAPBIRC3CASP9CYP3A4 | |
| SCHEMBL820264 | 0.79 | MTNR1A (0.41) | CYP3A4DRD2DRD4DRD3CYP2C9 | |
| SCHEMBL820272 | 0.79 | MTNR1A (0.37) | XIAPCASP9CYP3A4DRD2DRD4 | |
| SCHEMBL817999 | 0.78 | MTNR1A (0.34) | BIRC2XIAPBIRC3CASP9CYP3A4 | |
| SCHEMBL28789671 | 0.78 | DRD4 (0.47) | CYP3A4DRD2DRD4DRD3 | |
| SCHEMBL818209 | 0.78 | DRD4 (0.43) | DRD2DRD4DRD3 | |
| SCHEMBL823068 | 0.78 | DRD4 (0.43) | DRD2DRD4DRD3 | |
| SCHEMBL823066 | 0.76 | MTNR1A (0.38) | DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288116-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUITCAL CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2009094287-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICAL CORPORATION (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288116-A1 | IAP INHIBITORS | XIAP, BIRC5, BIRC7 | BIRC2 4/4885XIAP 1/4885BIRC3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.